• Oppose Independent Payment Advisory Board (IPAB). Medicare Part B Drug Reimbursement.
• Monitor Appropriations and Continuing Resolutions.
• Extend and expand Therapeutic Discovery Project (IRC 48D); capital formation tax policy; extend and expand R&D tax credit; monitor tax reform. S.3595, H.R.6559 to allow for certain high technology and biotechnology company to be eligible for Research and Development partnerships. S. 3232, a bill to extend and expand the Therapeutic Discovery Project Tax Credit Program. Advocate for improvements to the Internal Revenue Code Section 382 Net Operating Loss rules, Internal Revenue Code Section 1202 Small Business Capital gains rules and a more generous amortization period for Internal Revenue Code Section 197 intangibles. Amend and extend the Vaccine excise tax: S.3716; H.R. 6687. H.R. 475, Amend Vaccine Excise Tax.

Duration: January 1, 2008 to March 15, 2013

General Issues: Health Issues, Budget/Appropriations, Taxation/Internal Revenue Code, Copyright/Patent/Trademark, Energy/Nuclear

Spending: about $1,720,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2008: U.S. Senate, House of Representatives, Food & Drug Administration (FDA), House of Representatives, Senate, Treasury, Dept of, Transportation, Dept of (DOT), U.S. Senate,, Energy - Dept of, Office of Management & Budget (OMB), Executive Office of the President (EOP)